Scarica l'app Stockscreener
2.79
5.74%
-0.17
Dopo l'orario di chiusura:
2.78
-0.01
-0.36%
Precedente Chiudi:
$2.96
Aprire:
$2.92
Volume 24 ore:
1.48M
Relative Volume:
1.19
Capitalizzazione di mercato:
$247.92M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-14.42%
1M Prestazione:
-15.45%
6M Prestazione:
+60.34%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.71
$2.92
Intervallo di 1 settimana:
$2.71
$3.26
Portata 52W:
$1.42
$4.66
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
2.79 | 247.92M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
aTyr Pharma to Participate in April Investor Conferences - GlobeNewswire
Biotech Innovator aTyr Pharma Sets Key Investor Meetings at Premier Healthcare Conferences - Stock Titan
Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - MarketScreener
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? - Insider Monkey
aTyr Pharma appoints new head for efzofitimod program By Investing.com - Investing.com South Africa
aTyr Pharma appoints new head for efzofitimod program - Investing.com
ATyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise - MarketScreener
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewswire
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Victory Capital Management Inc. Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Insider Buying: Jane Gross Acquires Additional Shares of aTyr Ph - GuruFocus.com
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atyr, FDA align on efzofitimod trial analysis for pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments - Markets Insider
Reviewing Atyr PHARMA (NASDAQ:ATYR) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations By Investing.com - Investing.com Australia
aTyr Pharma’s Earnings Call Highlights Progress and Challenges - TipRanks
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha
Cantor Fitzgerald maintains Overweight on aTyr Pharma stock - Investing.com India
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... - Yahoo Finance
aTyr Pharma shares fall as Q4 loss narrows - Investing.com India
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... By GuruFocus - Investing.com Canada
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising Clinical Developments - GuruFocus.com
aTyr Pharma Reports 2024 Results and Strategic Progress - TipRanks
Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations - Investing.com
aTyr Pharma Inc Reports Q4 2024 Earnings: EPS of -$0.18 Beats Es - GuruFocus.com
aTYR PHARMA INC SEC 10-K Report - TradingView
aTyr Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atyr Pharma: Q4 Earnings Snapshot - mySA
aTyr Pharma shares fall as Q4 loss narrows By Investing.com - Investing.com South Africa
ATYR PHARMA Earnings Results: $ATYR Reports Quarterly Earnings - Nasdaq
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - The Manila Times
aTyr Pharma Hits Major Phase 3 Milestone with $94M War Chest for Sarcoidosis Drug - StockTitan
aTyr Pharma’s efzofitimod shows promise in ILD treatment By Investing.com - Investing.com Canada
aTyr Pharma’s efzofitimod shows promise in ILD treatment - Investing.com India
aTyr Pharma Announces Publication Demonstrating - GlobeNewswire
aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine - The Manila Times
Breakthrough: New Science Study Reveals How Efzofitimod Fights Chronic Inflammation - StockTitan
aTyr Pharma, Inc. to Host Earnings Call - ACCESS Newswire
Atyr Pharma Shares Rise After Lung Disease Treatment Passes Safety Review - MarketWatch
aTyr Pharma: Attractive Buy Opportunity Amid Positive Phase 2 Data and Anticipated Phase 3 Catalysts - TipRanks
aTyr rises after safety update on lead program - Seeking Alpha
aTyr Pharma Announces Fourth Positive DSMB Review for - GlobeNewswire
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):